These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim KS. Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2252-60. PubMed ID: 23868944 [Abstract] [Full Text] [Related]
27. Initial SYNTAX score predicts major adverse cardiac events after primary percutaneous coronary intervention. Brown AJ, McCormick LM, Gajendragadkar PR, Hoole SP, West NE. Angiology; 2014 May; 65(5):408-12. PubMed ID: 23574751 [Abstract] [Full Text] [Related]
28. Impact of cigarette smoking on extent of coronary artery disease and prognosis of patients with non-ST-segment elevation acute coronary syndromes: an analysis from the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). Robertson JO, Ebrahimi R, Lansky AJ, Mehran R, Stone GW, Lincoff AM. JACC Cardiovasc Interv; 2014 Apr; 7(4):372-9. PubMed ID: 24630881 [Abstract] [Full Text] [Related]
29. Usefulness of tissue Doppler imaging-myocardial performance index in the evaluation of diastolic dysfunction and heart failure with preserved ejection fraction. Kim H, Yoon HJ, Park HS, Cho YK, Nam CW, Hur SH, Kim YN, Kim KB. Clin Cardiol; 2011 Aug; 34(8):494-9. PubMed ID: 21780137 [Abstract] [Full Text] [Related]
30. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Buller CE, Fu Y, Mahaffey KW, Todaro TG, Adams P, Westerhout CM, White HD, van 't Hof AW, Van de Werf FJ, Wagner GS, Granger CB, Armstrong PW. Circulation; 2008 Sep 23; 118(13):1335-46. PubMed ID: 18779444 [Abstract] [Full Text] [Related]
31. Value of early cardiovascular magnetic resonance for the prediction of adverse arrhythmic cardiac events after a first noncomplicated ST-segment-elevation myocardial infarction. Izquierdo M, Ruiz-Granell R, Bonanad C, Chaustre F, Gomez C, Ferrero A, Lopez-Lereu P, Monmeneu JV, Nuñez J, Chorro FJ, Bodi V. Circ Cardiovasc Imaging; 2013 Sep 23; 6(5):755-61. PubMed ID: 23926195 [Abstract] [Full Text] [Related]
32. Optimized Prognosis Assessment in ST-Segment-Elevation Myocardial Infarction Using a Cardiac Magnetic Resonance Imaging Risk Score. Stiermaier T, Jobs A, de Waha S, Fuernau G, Pöss J, Desch S, Thiele H, Eitel I. Circ Cardiovasc Imaging; 2017 Nov 23; 10(11):. PubMed ID: 29122844 [Abstract] [Full Text] [Related]
34. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials. Garg S, Sarno G, Serruys PW, Rodriguez AE, Bolognese L, Anselmi M, De Cesare N, Colangelo S, Moreno R, Gambetti S, Monti M, Bristot L, Bressers M, Garcia-Garcia HM, Parrinello G, Campo G, Valgimigli M, STRATEGY and MULTISTRATEGY Investigators. JACC Cardiovasc Interv; 2011 Jan 23; 4(1):66-75. PubMed ID: 21251631 [Abstract] [Full Text] [Related]